Deal Summary
Premier Biotech announced the acquisition of point‑of‑care diagnostics provider NexScreen and drug‑testing product supplier TransMed, expanding its global footprint and product portfolio across healthcare, government and workplace markets. The deals add capabilities in Australia, New Zealand and an extensive e‑commerce platform, bringing Premier’s total acquisitions to seven since 2022. Financial terms were not disclosed.
Comments
Want to join the conversation?
Loading comments...